CONTEXT: Soluble adenylyl cyclase (sAC) is an enzyme that generates cyclic adenosine monophosphate, a signaling molecule involved in regulating melanocyte functions. R21, a mouse monoclonal antibody against sAC, shows a striking pan-nuclear staining in lentigo maligna, indicating possible utility for diagnosis and margin assessment. OBJECTIVE: To evaluate R21 in the diagnosis and evaluation of margins in lentigo maligna. DESIGN: Thirty one re-excision specimens for lentigo maligna were evaluated for R21 expression using previously published protocol. In addition, 153 cases including 41 lentigo malignas, 30 non-lentigo maligna-type melanomas, 38 lentigos, and 44 nevi were evaluated using a modified stringent protocol to eliminate all nonmelanocyte staining. RESULTS: The sensitivity of nuclear staining with R21 in lentigo maligna was 87.8%. Nuclear expression of sAC was observed in 40% of other melanomas and 2.3% of benign nevi. R21 did not stain nuclei of resting melanocytes but was observed in 28.9% of melanocytic hyperplasias. These cases were easily distinguished from lentigo maligna in routine sections. R21 staining facilitated extent of the lesion in resection margins. In cases examined under the less stringent conditions, interpretation was facilitated by comparing R21 and Mart1/Melan A staining. Greater than 9 pan-nuclear staining melanocytes within one high-power field along with a pan-nuclear sAC/Melan A ratio greater than 0.5 was consistent with a positive margin whereas 5 or less pan-nuclear staining melanocytes along with a sAC/Melan A ratio of less than 0.3 constituted a negative margin. CONCLUSION: R21 is a useful diagnostic adjunct in the diagnosis and evaluation of margins in re-excision specimens in lentigo maligna.
CONTEXT: Soluble adenylyl cyclase (sAC) is an enzyme that generates cyclic adenosine monophosphate, a signaling molecule involved in regulating melanocyte functions. R21, a mouse monoclonal antibody against sAC, shows a striking pan-nuclear staining in lentigo maligna, indicating possible utility for diagnosis and margin assessment. OBJECTIVE: To evaluate R21 in the diagnosis and evaluation of margins in lentigo maligna. DESIGN: Thirty one re-excision specimens for lentigo maligna were evaluated for R21 expression using previously published protocol. In addition, 153 cases including 41 lentigo malignas, 30 non-lentigo maligna-type melanomas, 38 lentigos, and 44 nevi were evaluated using a modified stringent protocol to eliminate all nonmelanocyte staining. RESULTS: The sensitivity of nuclear staining with R21 in lentigo maligna was 87.8%. Nuclear expression of sAC was observed in 40% of other melanomas and 2.3% of benign nevi. R21 did not stain nuclei of resting melanocytes but was observed in 28.9% of melanocytic hyperplasias. These cases were easily distinguished from lentigo maligna in routine sections. R21 staining facilitated extent of the lesion in resection margins. In cases examined under the less stringent conditions, interpretation was facilitated by comparing R21 and Mart1/Melan A staining. Greater than 9 pan-nuclear staining melanocytes within one high-power field along with a pan-nuclear sAC/Melan A ratio greater than 0.5 was consistent with a positive margin whereas 5 or less pan-nuclear staining melanocytes along with a sAC/Melan A ratio of less than 0.3 constituted a negative margin. CONCLUSION: R21 is a useful diagnostic adjunct in the diagnosis and evaluation of margins in re-excision specimens in lentigo maligna.
Authors: Jonathan H Zippin; Yanqiu Chen; Patrick Nahirney; Margarita Kamenetsky; Mark S Wuttke; Donald A Fischman; Lonny R Levin; Jochen Buck Journal: FASEB J Date: 2002-11-15 Impact factor: 5.191
Authors: Ali Hendi; David A Wada; M Amanda Jacobs; Julia E Crook; Kimberly R Kortuem; Brent R Weed; Clark C Otley; Lawrence E Gibson Journal: J Am Acad Dermatol Date: 2011-06-17 Impact factor: 11.527
Authors: Jonathan H Zippin; Jeanne Farrell; David Huron; Margarita Kamenetsky; Kenneth C Hess; Donald A Fischman; Lonny R Levin; Jochen Buck Journal: J Cell Biol Date: 2004-02-09 Impact factor: 10.539
Authors: Cristina Salmerón; Till S Harter; Garfield T Kwan; Jinae N Roa; Salvatore D Blair; Jodie L Rummer; Holly A Shiels; Greg G Goss; Rod W Wilson; Martin Tresguerres Journal: Interface Focus Date: 2021-02-12 Impact factor: 3.906
Authors: Lavoisier Ramos-Espiritu; Ana Diaz; Charlee Nardin; Anthony J Saviola; Fiona Shaw; Tamar Plitt; Xia Yang; Jedd Wolchok; Edyta C Pirog; Garrett Desman; Andrea Sboner; Tuo Zhang; Jenny Xiang; Taha Merghoub; Lonny R Levin; Jochen Buck; Jonathan H Zippin Journal: Oncotarget Date: 2016-07-19